ddp4 and glp 1 together Mechanism of action for GIP, GLP-1 analogues DPP4 inhibitors in GLP-1/GLP-1R: The Star Target for
Description
Diabetes, Obesity and Metabolism, 27(1), 4556

Moving Beyond Lifestyle Benefits Traditionally, employer-sponsored weight management programs, such as wellness support, gym reimbursement, and nutrition counseling, have been classified as "lifestyle benefits." However, as GLP-1 therapies gain FDA approval for cardiovascular, kidney, metabolic, and sleep-related conditions, treating them as lifestyle benefits ignores their role in preventing high-cost chronic disease and shifts avoidable risk back onto employers
Rapid weight loss itself can trigger temporary mood shifts

The benefits observed in studies to date depend on achieving and maintaining therapeutic dose ranges over time

It simply sets the expectations

This case series provides patient-level data that complement the findings of a meta-analysis by He et al of the association of cholecystitis with GLP-1 receptor agonists, the researchers wrote
